Loading
Journal of Clinical Cardiology
ISSN: 2694-5088
Latest Articles
From Comorbidity to Phenotype: Redefining Risk in Cardiorenal Acute Kidney Injury
Brent Tai , Chijioke Okonkwo , Yaroslav Zuyev , Derek Synder
Acute kidney injury (AKI) in hospitalized patients is increasingly recognized as part of a broader cardiorenal metabolic process rather than an isolated renal event. Heart failure (HF) and diabetes mellitus (DM) frequently coexist among patients at risk for AKI and contribute to hemodynamic, neurohormonal, and metabolic disturbances that influence clinical outcomes. However, current risk stratification approaches often evaluate these conditions independently, potentially overlooking their interactive effects.
J Clin Cardiol, 2026, Volume 7, Issue 2, p79-82 | DOI: 10.33696/cardiology.7.095
From Clinics to Communities: Precision Prevention for Cardiovascular Health in South Asians
Kristina M. Wang , Rushabh H. Doshi , Kanhai S. Amin , Pavan Khosla
Cardiovascular disease in Asian Americans represents a paradox of increasing demographic prominence yet persistent scientific underrecognition. Despite being one of the fastest-growing populations in the United States, Asian Americans remain underrepresented in cardiovascular research and poorly characterized in risk prediction frameworks.
J Clin Cardiol, 2026, Volume 7, Issue 2, p101-104 | DOI: 10.33696/cardiology.7.098
Do We Need ICDs for Prevention of SCD in Patients with Monomorphic Ventricular Tachycardia? – Only Time Will Tell!
Jakub Tomala , Christopher Kowalewski , Ilkin Maharramli , Thomas Winkler , Arno P. Bößenecker , Andrea Brinker-Paschke , Matthias Pauschinger , Thomas Deneke
While the concept of catheter ablation (CA) as first-line therapy of ventricular tachycardia (VT) is not new, its widespread adoption has been hindered by the lack of supporting data. The ever-present risk of sudden cardiac death (SCD) associated with VT and proven efficacy of implantable cardioverter defibrillators (ICD) have made it difficult to justify withholding an ICD implantation even after effective CA in patients with structural heart disease.
J Clin Cardiol, 2026, Volume 7, Issue 2, p95-100 | DOI: 10.33696/cardiology.7.097
Palliative and Hospice Measures for Patients with End-Stage Heart Failure
Zayd Parekh , Sultan Ahmed , Saad Rashid , Santhanam Kumar , Jon Monkemeyer , Rashad Belin
End-stage heart failure (ESHF) represents a phase of progressive disease characterized by refractory symptoms, frequent hospitalizations, high mortality, and substantial physical and psychosocial burden for patients and caregivers. Despite advances in guideline-directed medical therapy and device-based interventions, many patients with ESHF experience diminished quality of life and face complex decisions regarding advanced therapies and end-of-life care.
J Clin Cardiol, 2026, Volume 7, Issue 2, p83-94 | DOI: 10.33696/cardiology.7.096